Analytical Data
-
Gene name
BRD9
- Application
-
Alternative Names
BRD9; UNQ3040/PRO9856Bromodomain-containing Protein 9; Rhabdomyosarcoma antigen MU-RMS-40.8
-
Species
Human
-
Source
E. coli
-
Tag
GST-tag at N-terminal
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9H8M2
-
Expression Region
1-481aa
-
AA Sequence
MKGYQSLVFNFFFLKLSAENESTPIQQLLEHFLRQLQRKDPHGFFAFPVTDAIAPGYSMIIKHPMDFGTMKDKIVANEYKSVTEFKADFKLMCDNAMTYNRPDTVYYKLAKKILHAGFKMMSKQAALLGNEDTAVEEPVPEVVPVQVETAKKSKKPSREVISCMFEPEGNACSLTDSTAEEHVLALVEHAADEARDRINRFLPGGKMGYLKRNGDGSLLYSVVNTAEPDADEEETHPVDLSSLSSKLLPGFTTLGFKDERRNKVTFLSSATTALSMQNNSVFGDLKSDEMELLYSAYGDETGVQCALSLQEFVKDAGSYSKKVVDDLLDQITGGDHSRTLFQLKQRRNVPMKPPDEAKVGDTLGDSSSSVLEFMSMKSYPDVSVDISMLSSLGKVKKELDPDDSHLNLDETTKLLQDLHEAQAERGGSRPSSNLSSLSNASERDQHHLGSPSRLSVGEQPDVTHDPYEFLQSPEPAASAKT
-
Molecular Weight
79.6 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
BRD9 is a member of the bromodomain and extraterminal (BET) family of proteins, which are known to play critical roles in regulating gene expression through their interactions with acetylated lysines on histones and non-histone proteins. The study of BRD9 has garnered significant interest due to its involvement in various biological processes, including chromatin remodeling and transcriptional regulation. Recent research has shown that BRD9 is associated with several cellular functions, such as cell proliferation, differentiation, and response to stress, making it a potential target for therapeutic interventions in cancer and other diseases. The characterization of BRD9 recombinant proteins is essential for understanding its structural and functional properties, as well as its role in diseases. By producing and studying BRD9 in a recombinant form, researchers can investigate its interactions with other proteins, elucidate its biochemical pathways, and explore its potential as a drug target. This research contributes to the broader understanding of epigenetic regulation and opens new avenues for developing targeted therapies aimed at modulating BRD9's activity to combat various pathological conditions.
